Trial Search Results

A Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Subjects With Ichthyosis

Efficacy and Safety of ANB019 in Subjects with Ichthyosis

Stanford is currently accepting patients for this trial.

Lead Sponsor:

AnaptysBio, Inc.

Stanford Investigator(s):

Intervention(s):

  • Drug: ANB019
  • Biological: placebo

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Diagnosis of Ichthyosis

   - IASI total score ≥ 18, erythema score ≥ 2

   - Subject has been using emollient daily for at least 1 week prior to Day 1 and agrees
   to continue using that same emollient daily at the same frequency throughout the study

Exclusion Criteria:

   - A subject with ichthyosis vulgaris, X-linked ichthyosis, or lamellar ichthyosis will
   be excluded.

Ages Eligible for Study

12 Years - 75 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Recruiting